Tenax Therapeutics Inc (TENX)

[makingbiigdough]

HERE YOU GO MY FRIEND! THANK GOD I COULD COPY NEWS ARTICLE!! MBD

In response to the pneumonia epidemic of new coronavirus infection, the National Health and Medical Commission issued the "Pneumonitis Diagnosis and Treatment Program for New Coronavirus Infection (Trial Version 4)", which provides clear guidance for clinical diagnosis and treatment. The article points out that the clinical manifestations of patients with viral infection are mainly fever, fatigue, dry cough, and severe cases progress rapidly to acute respiratory distress syndrome, septic shock, difficult to correct metabolic acidosis and coagulopathy.


In the above clinical manifestations, septic shock is one of the more serious cases. In patients with pneumonitis infected by the new coronavirus, sepsis may occur when antibiotics are not optimally controlled. The incidence of sepsis is about 1.5% and the mortality rate is 10%, of which about 4% develop septic shock. Sepsis-related myocardial depression is called septic cardiomyopathy, and the mortality rate is as high as 50 to 70% when septic shock occurs.


In the "New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (Trial Version 4)", for the treatment of severe and critical cases, the need for circulatory support was clearly stated, that is,


Levosimendan as a calcium sensitizer can increase cardiac output without significant changes in heart rate and myocardial oxygen consumption. In addition to improving hemodynamics, it can also improve tissue microcirculation in patients with sepsis . More importantly, Levosimendan is a long-acting heart-strengthening medicine. The injection of a single dose of Levosimendan can maintain its effect for 7-10 days.


In clinical use, a levosimendan combined with 250ml of 5% glucose solution is recommended for intravenous infusion using an infusion pump. A direct maintenance dose of 0.1 µg / kg / min is recommended for 24 hours of infusion. If the patient's blood pressure is very low, the recommended dose starts from 0.05 µg / kg / min, and after about 3 hours, the dose is adjusted to 0.1 µg / kg / min according to the patient's condition.



[Common name] Levosimendan injection

[Ingredients] Levosimendan, absolute ethanol, polyethylene glycol 400, citric acid.

[Indications] Short-term treatment of acute decompensated heart failure (ADHF).

[Dosage]

The initial loading dose is 6-12 µg / kg, the administration time is not shorter than 10 min, and then the continuous infusion is 0.1 µg / kg / min. Adjust the infusion rate between 0.05 and 0.2 µg / kg / min according to the patient's tolerance and response. The administration time for patients with acute decompensated heart failure is usually 24 hours. Monitor the ECG, blood pressure, and heart rate.

[Adverse reactions]

The most common adverse reactions were headache and hypotension. For other adverse reactions, please refer to the instructions.

[Taboo]

1. Mechanical obstructive disease that significantly affects ventricular filling or / and ejection function;

2. Severe liver and kidney (creatinine clearance

3. Patients with severe hypotension and tachycardia;

4. Patients with a history of torsional ventricular tachycardia;

5. Patients who are allergic to levosimendan or any other excipient.

[Precautions]

1. For patients with low basal blood pressure and patients at risk for hypotension, a more conservative dose is recommended;

2. Severe hypovolemia should be corrected before medication, if the blood pressure or heart rate changes excessively, the infusion rate should be reduced or the drug should be discontinued;

3. The hemodynamic effect of this product lasts for 7 ~ 10 days. After the infusion, the blood pressure should be monitored non-invasively until the blood pressure starts to rise;

4. Use with caution in patients with mild to moderate renal impairment and patients with mild to moderate liver impairment;

5. The abnormal blood potassium concentration should be corrected before medication, and the blood potassium concentration should be monitored during treatment.

Please refer to the instructions for other precautions.

For medical professionals only